BP
CBPO

BFAM Partners’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

BFAM Partners’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-127,195
Closed -$13.7M – 20
2020
Q1 		$13.7M Buy
+127,195
New +$14.6M 8.27% 4

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

BFAM Partners's CBPO Position: Q2 2020 in Review

BFAM Partners sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2020, closing a stake of 127,195 shares — an estimated $13.7M sold.

BFAM Partners first reported a position in CBPO in Q1 2020 and held it in 1 quarter. The position peaked at $13.7M in Q1 2020. 91 funds tracked by Wall St. Rank hold CBPO as of Q2 2020.

  • BFAM Partners reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2020 after selling out during the quarter.
  • BFAM Partners sold 127,195 China Biologic Products Holdings, Inc. shares in Q2 2020, an estimated $13.7M.
  • BFAM Partners first reported a position in China Biologic Products Holdings, Inc. in Q1 2020 and held it in 1 quarter.
  • BFAM Partners's China Biologic Products Holdings, Inc. position peaked at $13.7M in Q1 2020.
  • 91 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2020.

Based on BFAM Partners's 13F filing for Q2 2020, filed 12 Aug 2020.